Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Human Virome01:26

Human Virome

The human body harbors a vast and diverse viral community known as the human virome. The virome includes bacteriophages that infect bacteria, and eukaryotic viruses that infect human cells. Transient dietary and environmental viruses also contribute to this dynamic ecosystem. Estimates suggest the human body may contain on the order of 10¹³ viral particles, though abundance varies widely by body site and detection method.Comprehensive characterization of the virome has become possible only with...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distribution of divalent small interfering RNA into neurons of sensory ganglia produces selective, durable knockdown of Nav1.7 and strong analgesia.

Pain·2026
Same author

Divalent siRNA for prion disease.

Nucleic acids research·2026
Same author

Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHD.

Nucleic acids research·2026
Same author

Divalent siRNA for prion disease.

bioRxiv : the preprint server for biology·2026
Same author

Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

The New England journal of medicine·2026
Same journal

Aptamers: Current Applications in Leukemia Diagnostics and Therapeutics.

Nucleic acid therapeutics·2026
Same journal

Exploring Clearance Pathways for GalNAc-siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications.

Nucleic acid therapeutics·2026
Same journal

Unraveling the Stereochemical Complexity of Phosphorothioate-Modified Oligonucleotides Using Analytical Technologies.

Nucleic acid therapeutics·2026
Same journal

Rat and Rabbit Whole-Embryo Culture as a New Approach Method for Unlabeled Therapeutic Antisense Oligonucleotide Hazard Identification with No Requirement for Microinjection or Assisted Transfection.

Nucleic acid therapeutics·2026
Same journal

Programmable RNA Editing via Adenosine Deaminase Acting on RNA Enzymes: Current Advances and Clinical Potential.

Nucleic acid therapeutics·2026
Same journal

Efficient Downregulation of Flt-1 Mediated by Splice Switching ASO in Murine Endothelial Cells.

Nucleic acid therapeutics·2026
See all related articles

Related Experiment Video

Updated: May 19, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Developing microRNA therapeutics: approaching the unique complexities.

Aimee L Jackson1, Arthur A Levin

  • 1Jackson BioConsulting, San Diego, California 92130, USA. aimee.jackson40@gmail.com

Nucleic Acid Therapeutics
|August 24, 2012
PubMed
Summary
This summary is machine-generated.

MicroRNAs regulate gene expression and are crucial for biological functions. Targeting microRNAs offers a novel therapeutic strategy for diseases like hepatitis C, though challenges remain in drug development.

More Related Videos

High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs
07:27

High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs

Published on: August 3, 2011

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Related Experiment Videos

Last Updated: May 19, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs
07:27

High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs

Published on: August 3, 2011

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are small, endogenous non-coding RNAs.
  • They regulate gene expression post-transcriptionally by targeting mRNA stability and translation.
  • Dysregulation of miRNA expression is linked to various disease phenotypes.

Purpose of the Study:

  • To highlight the therapeutic potential of microRNAs.
  • To discuss microRNA modulators as a novel class of drugs.
  • To identify challenges in developing miRNA-based therapeutics.

Main Methods:

  • Review of current literature on microRNA biology and function.
  • Analysis of disease associations with microRNA mutations or altered expression.
  • Examination of recent clinical findings, such as miR-122 inhibition in hepatitis C.

Main Results:

  • MicroRNAs play vital roles in maintaining biological homeostasis.
  • Aberrant miRNA expression is implicated in numerous human diseases.
  • Successful inhibition of miR-122 in hepatitis C demonstrates therapeutic viability.

Conclusions:

  • MicroRNA modulators represent a promising new therapeutic avenue.
  • Targeting microRNAs offers a novel mechanism for disease intervention.
  • Further research is needed to overcome challenges in miRNA-based drug development.